Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Study explores vastly reducing time needed for treatment-resistant depression therapy

Study explores vastly reducing time needed for treatment-resistant depression therapy

Stories Oct 2, 2015 3 minutes

Repetitive transcranial magnetic stimulation offers effective, accessible, minimal side-effects option to medication.

As though suffering from depression was not challenging and debilitating enough, some sufferers find no relief from treatment or experience side effects to medications that make taking them impossible. An estimated 22 per cent of Canadians with major depressive disorder have such treatment-resistant depression (TRD). While the situation may seem hopeless, one therapy called repetitive transcranial magnetic stimulation (rTMS) has shown significant efficacy as a non-invasive procedure with minimal side effects, offering a viable treatment option. Vancouver Coastal Health Research Institute scientist Dr. Fidel Vila-Rodriguez is hoping to find a way to make rTMS more accessible and available to people with TRD.

 “There’s a huge need to find alternative treatments that don’t have such harsh side effects or that provide relief for people with TRD,” says Dr. Vila-Rodriguez, clinical associate professor in the Department of Psychiatry at the University of British Columbia (UBC) and director of the Non-Invasive Neurostimulation Laboratory & Schizophrenia Program at UBC Hospital. 

“That’s where rTMS has found its role because according to the latest meta-analysis it reaches an efficacy rate that’s very high for treating TRD: 50 to 55 per cent response rate and 30 to 35 per cent remission rate.”

rTMS involves using a pulsating magnetic field to stimulate targeted areas of the brain. How exactly the therapy works is not completely understood, however, repeated TMS treatments seem to improve how these brain areas and circuits operate and help with depressive symptoms in some people. TRD patients prescribed rTMS typically have to receive the treatment for 40 minutes every day for six weeks.

Dr. Vila-Rodriguez is leading at UBC a multicentre study to determine whether a new stimulation protocol that reduces the time needed for each treatment to only three minutes (rather than 40) is as effective as conventional treatment standards. He is also examining the efficacy of a new method of stimulation called theta burst. 

“These two possible changes will impact the availability and capacity of clinics to offer the treatment to more people,” he says.

“If our hypothesis of the study is supported by data, there will be two groups for whom this research will benefit: for patients receiving treatment, the shortened treatment time will be a lot more convenient and will make the visit to the clinic almost as short as a coffee break,” says Dr. Vila-Rodriguez. “And it’s a game-changer for clinical practice because suddenly an appointment that would normally take an hour could be reduced to 15 minutes, which is a generous estimate."

"By increasing the capacity of the clinic, the cost of having a device and personnel is reduced and the system becomes more efficient.”

Switching to the theta burst method of stimulation would deliver more stimuli within each burst.

“Theta burst is a good tool is because the rhythm of five (theta) bursts per second actually mimics a rhythm that we all have in our brains,” explains Dr. Vila-Rodriguez. “It seems that certain parts of our brain communicate at that rhythm and that’s why earlier studies were completed trying this type of stimulation.”

“The fact that rTMS offers minor side effects such as mild discomfort or headaches, or the rare possibility of a seizure during stimulation, make it a better suited treatment for many people suffering from TRD,” he adds. “What I’m envisioning is that really rTMS can be a treatment that can be incorporated into someone’s schedule easily without much interference in their daily life.”

The study, which is a collaborative effort between Dr. Vila-Rodriguez’s lab and the Centre for Addictions and Mental Health (Toronto) and Toronto Western Hospital, aims to recruit 300 participants between the three sites. 


Visit Ninet for more information about how to participate.

 

Researchers

Fidel Vila-Rodriguez

Related Articles

Right-side low-frequency rTMS improved major depressive symptoms

The mood-memory connection in treatment-resistant depression

New guide for patients with treatment-resistant depression

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Djavad Mowafaghian Centre for Brain Health

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy